$7.9283
0.0883[1.13%]
Last update: 2:27PM Get Real Time Here
Eliem Therapeutics
(NASDAQ:ELYM)Eliem Therapeutics Stock (NASDAQ:ELYM), Analyst Ratings, Price Targets, Predictions
Eliem Therapeutics Inc has a consensus price target of $11.25, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on March 8, 2023, February 10, 2023, and October 28, 2022. With an average price target of $4 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied -49.55% downside for Eliem Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
SVB Leerink
Guggenheim
Stifel
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Eliem Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/08/2023 | Buy Now | -24.32% | HC Wainwright & Co. | Douglas Tsao | → $6 | Reiterates | → Neutral | Get Alert |
| 02/10/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | — | Downgrade | Buy → Neutral | Get Alert |
| 10/28/2022 | Buy Now | -24.32% | HC Wainwright & Co. | Douglas Tsao | → $6 | Initiates | → Buy | Get Alert |
| 08/16/2022 | Buy Now | -49.55% | SVB Leerink | Marc Goodman | $9 → $4 | Maintains | Outperform | Get Alert |
| 07/11/2022 | Buy Now | 13.52% | SVB Leerink | Marc Goodman | $13 → $9 | Maintains | Outperform | Get Alert |
| 04/26/2022 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 04/26/2022 | Buy Now | 63.97% | SVB Leerink | Marc Goodman | $33 → $13 | Maintains | Outperform | Get Alert |
| 09/07/2021 | Buy Now | 303.62% | Guggenheim | Yatin Suneja | — | Initiates | → Buy | Get Alert |
| 09/07/2021 | Buy Now | 341.46% | Stifel | Paul Matteis | — | Initiates | → Buy | Get Alert |
| 09/07/2021 | Buy Now | 316.23% | SVB Leerink | Marc Goodman | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Eliem Therapeutics (ELYM)?
The latest price target for Eliem Therapeutics (NASDAQ: ELYM) was reported by HC Wainwright & Co. on March 8, 2023. The analyst firm set a price target for $6.00 expecting ELYM to fall to within 12 months (a possible -24.32% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Eliem Therapeutics (ELYM)?
The latest analyst rating for Eliem Therapeutics (NASDAQ: ELYM) was provided by HC Wainwright & Co., and Eliem Therapeutics reiterated their neutral rating.
When was the last upgrade for Eliem Therapeutics (ELYM)?
There is no last upgrade for Eliem Therapeutics.
When was the last downgrade for Eliem Therapeutics (ELYM)?
The last downgrade for Eliem Therapeutics Inc happened on February 10, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Eliem Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Eliem Therapeutics (ELYM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eliem Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eliem Therapeutics was filed on March 8, 2023 so you should expect the next rating to be made available sometime around March 8, 2024.
Is the Analyst Rating Eliem Therapeutics (ELYM) correct?
While ratings are subjective and will change, the latest Eliem Therapeutics (ELYM) rating was a reiterated with a price target of $0.00 to $6.00. The current price Eliem Therapeutics (ELYM) is trading at is $7.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.